CSL Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gordon Naylor
- Full Time Employees
- 29,000
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 655 Elizabeth Street Melbourne VIC Australia 3000
- IPO Date
- Jun 8, 1994
- Website
- csl.com.au
- Similar Companies
- Business
- CSL Limited is an Australian multinational specialty biotechnology company focused on the research, development, manufacture, and marketing of biopharmaceutical products to treat and prevent rare and serious diseases globally. Its core operations are divided into three main business units: CSL Behring, which develops therapies including immunoglobulins, albumin, and coagulation products; CSL Seqirus, a global leader in influenza vaccines and pandemic preparedness; and CSL Vifor, which specializes in treatments for iron deficiency, nephrology, and cardio-renal diseases. The company operates extensively across the Americas, Europe, Asia, and Australia, with a strong manufacturing and R&D presence headquartered in Melbourne, Australia. Founded in 1916 as Commonwealth Serum Laboratories, CSL has evolved into a global biotech leader. Recent major developments include CSL’s $1.5 billion investment to expand its manufacturing footprint in the United States, reinforcing its leadership in plasma-derived therapies. The company has formed strategic partnerships such as a Memorandum of Understanding with Saudi Arabia’s Ministry of Health to localize influenza vaccine manufacturing. CSL has also expanded through acquisitions and collaborations, notably completing the $11.7 billion acquisition of Swiss-based Vifor Pharma AG in 2021, substantially enhancing its portfolio in iron deficiency and nephrology treatments. In 2025, CSL entered a strategic collaboration and option agreement with Dutch biotech company VarmX BV to develop a novel coagulation treatment. Additionally, CSL acquired an 80% stake in Chinese plasma fractionator Ruide, expanding its footprint in Asia. CSL continues advancing its immunoglobulin portfolio with new product launches such as Andembry and Hemgenix, while integrating operational and digital capabilities to accelerate product commercialization and improve manufacturing efficiency. CSL Limited targets healthcare providers, hospitals, governments, and patients requiring specialty therapies in immunology, hematology, vaccines, nephrology, and cardiology sectors. Its integrated global plasma network and manufacturing scale uniquely position it as a leader in biologics manufacturing and supply. The company’s pipeline is focused on innovative therapies in areas of high unmet medical need, supported by cross-functional portfolio leadership and a robust R&D strategy combining internal development with external partnerships. CSL’s comprehensive product range includes plasma-derived therapies, influenza vaccines, iron deficiency medicines, coagulation products, and emerging cell therapies. Its geographic operations span across more than 45 countries, with significant production facilities in the U.S., Australia, Europe, and Asia. The company remains committed to expanding its reach and innovation capacity through investments in manufacturing, strategic alliances, and market diversification initiatives.
Company News
CSL appoints Deborah Waterhouse as CEO & Managing Director
Australia's CSL appoints Deborah Waterhouse as CEO
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras
CSL strikes US$1.6 billion licensing deal for rare disease drug
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Australia's CSL taps Amazon's cloud unit to boost research pipeline
Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript
Australia's CSL reports 2% fall in annual profit
CSL Q2 Earnings Beat Estimates on Record Sales, Outlook Raised
CSL to start clinical trials for new immunoglobulin manufacturing process
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
CSL Delivers World's First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations
Australia says CSL unit Seqirus to discontinue Benpen injections from November
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript